CCO faculty Sara Hurvitz, MD, FACP, provides her thoughts on key studies in HER2+ breast cancer presented at the 2019 Breast Cancer meeting in San Antonio
Results from PEARL study of palbociclib with endocrine therapy in patients with HR+/HER- MBC and disease progression on prior AI therapy from SABCS 2019 as reported by Clinical Care Options (CCO)
Second interim OS analysis of SOPHIA trial of margetuximab + CT vs trastuzumab + CT for previously treated HER2+ MBC from SABCS 2019 as reported by Clinical Care Options
Results from plasmaMATCH trial using ctDNA testing to guide targeted therapy selection for patients with advanced breast cancer from SABCS 2019 as reported by Clinical Care Options (CCO)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.